Mizuho Raises Quest Diagnostics Price Target to $235, Maintains Outperform Rating

Mizuho analyst Ann Hynes has increased her price target for Quest Diagnostics (DGX) shares from $210.00 to $235.00, representing an 11.90% jump. The analyst also maintained an 'Outperform' rating on the diagnostic testing provider's stock. This positive adjustment aligns with several other market analysts who have similarly raised their price targets for the company. The move reflects a generally favorable sentiment among market watchers towards Quest Diagnostics. However, GuruFocus's estimated GF Value suggests a potential downside from the stock's current price, despite the positive analyst outlook.